Investors

Message from CEO

“Financial results for the first quarter of FY2017 were in line with our expectations and the previously announced consolidated forecasts. Although some development programs were discontinued, the rest of our development activities are progressing steadily, and the acquisition of Ogeda expanded Astellas’ late-stage clinical pipeline including fezolinetant,” said Yoshihiko Hatanaka, president and CEO, Astellas. “We remain committed to creating innovative medical solutions and delivering value for patients and all stakeholders, as we continue to advance our strategic plan through maximizing the product value, creating innovation and pursuing operational excellence.”